SFM
Sphera Funds Management Portfolio holdings
AUM
$422M
1-Year Est. Return
23.63%
1 Year Est. Return
+23.63%
AUM
$422M
AUM Growth
+$39.1M
(+10%)
Holding
127
Top Buys
| 1 | +$22.8M | |
| 2 | +$13.8M | |
| 3 | +$7.59M | |
| 4 |
Cellebrite
CLBT
|
+$5.54M |
| 5 |
RAPP
Rapport Therapeutics
RAPP
|
+$4.68M |
Top Sells
| 1 | +$18.2M | |
| 2 | +$10.2M | |
| 3 | +$9.9M | |
| 4 |
Cytokinetics
CYTK
|
+$9.08M |
| 5 |
NVIDIA
NVDA
|
+$8.61M |
Sector Composition
| 1 | Healthcare | 72.06% |
| 2 | Technology | 20.2% |
| 3 | Industrials | 0.82% |
| 4 | Consumer Discretionary | 0.72% |
| 5 | Communication Services | 0.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Teva Pharmaceuticals
TEVA
$30.9B
| $30.4M | 6.42% |
1,507,025
-113,965
|
|
||
2
Nice
NICE
$6.55B
| $22.8M | 4.81% |
+157,400
|
|
||
3
Tower Semiconductor
TSEM
$12.1B
| $22.5M | 4.76% |
311,802
+47,080
|
|
||
4
Nova
NVMI
$9.28B
| $14M | 2.96% |
43,896
-31,940
|
|
||
5
Invesco QQQ Trust
QQQ
$405B
| $13.8M | 2.91% |
+22,960
|
|
||
6
Biogen
BIIB
$26.7B
| $11.6M | 2.44% |
82,738
|
|
||
7
Ultragenyx Pharmaceutical
RARE
$3.35B
| $10.6M | 2.24% |
352,558
+252,473
|
|
||
8
AstraZeneca
AZN
$287B
| $10.4M | 2.19% |
135,060
|
|
||
9
Sanofi
SNY
$121B
| $10.4M | 2.19% |
219,515
|
|
||
|
10
Cytokinetics
CYTK
$8.33B
| $8.88M | 1.87% |
161,517
-165,201
|
|
||
11
Mineralys Therapeutics
MLYS
$3.41B
| $8.34M | 1.76% |
219,910
-261,064
|
|
||
12
Amicus Therapeutics
FOLD
$3.06B
| $7.81M | 1.65% |
991,142
+424
|
|
||
13
Eli Lilly
LLY
$963B
| $7.66M | 1.62% |
10,040
-1,500
|
|
||
14
Johnson & Johnson
JNJ
$499B
| $7.57M | 1.6% |
40,831
|
|
||
15
Cidara Therapeutics
CDTX
$6.91B
| $7.25M | 1.53% |
75,743
-62,258
|
|
||
16
Forte Biosciences
FBRX
$232M
| $7.11M | 1.5% |
474,309
-20,800
|
|
||
17
Syndax Pharmaceuticals
SNDX
$1.72B
| $5.97M | 1.26% |
387,716
-1,183,848
|
|
||
18
Trevi Therapeutics
TRVI
$1.69B
| $5.89M | 1.24% |
643,957
-156,000
|
|
||
19
Novo Nordisk
NVO
$219B
| $5.86M | 1.24% |
105,677
|
|
||
20
AbbVie
ABBV
$402B
| $5.85M | 1.23% |
25,256
|
|
||
|
21
Cellebrite
CLBT
$4.12B
| $5.54M | 1.17% |
+298,948
|
|
||
22
Annexon
ANNX
$671M
| $5.47M | 1.15% |
1,794,387
+30,000
|
|
||
23
Dyne Therapeutics
DYN
$3.13B
| $5.4M | 1.14% |
426,518
+205,102
|
|
||
24
Celldex Therapeutics
CLDX
$1.8B
| $5.37M | 1.13% |
207,764
-211,776
|
|
||
25
GSK
GSK
$96.6B
| $5.27M | 1.11% |
122,000
|
|